目的 考察舒脑欣滴丸单独或与华法林钠联合应用时抗凝血作用及对血小板聚集的影响。方法 采用比浊法, 体外测定对照组和舒脑欣滴丸低、高剂量(4.54、22.70 mg/mL)组的血小板聚集率;体内实验设对照组, 舒脑欣滴丸低、高剂量(45.36、90.72 mg/kg)组, 华法林钠(临床等效剂量0.4 mg/kg)组, 联合给药低、高剂量(舒脑欣滴丸45.36、90.72 mg/kg＋华法林钠0.4 mg/kg)组。大鼠ig给予舒脑欣滴丸及华法林钠3 d, 腹主动脉取血, 分离血小板, 采用比浊法测定血小板聚集率;分离血清利用半自动凝血仪测定实验各组活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)和凝血酶时间(TT)。结果 与对照组比较, 舒脑欣滴丸体外具有较强的抗血小板聚集作用, 在体内抑制血小板聚集作用随剂量的增大而略有增加。并且舒脑欣滴丸可以显著延长APTT、PT和TT;与单独用药组比较, 联合给药组对血小板聚集作用影响不明显, 但可显著延长大鼠APTT、PT和TT。结论 舒脑欣滴丸具有一定抑制血小板聚集和抗凝血作用;与华法林钠联用能够协同增强抗凝血作用。

Objective To study the anticoagulant effect of Shunaoxin Dropping Pill (SDP) alone or in combination with Warfarin sodium on platelet aggregation and provide the experimental support for the clinical safety of medication. Methods Experiments were carried out in control group, low-dose SDP group, high-dose SDP group (45.36 and 90.72 mg/kg), and Warfarin sodium (clinical equivalent dose 0.4 mg/kg) group, Combined administration with low-dose SDP and high-dose SDP groups + clinical equivalent dose of Warfarin sodium. We determined the platelet aggregation rate of rats in the control group, low-dose SDP group, and high-dose SDP group in vitro by turbidimetry. We made iac administration of SDP and Warfarin sodium for 3 d, and took abdominal aortic blood for separating the platelets and used nephelometry for determining platelet aggregation rate; We separated serum and used semi-automatic coagulation analyzer to test APTT, PT, and TT. Results Compared with the control group, SDP had the strong anti-platelet aggregation in vitro and could inhibit the increase of platelet aggregation in vivo slightly with the dose increasing. SDP could prolong APTT, PT, and PT; Compared with the single drug group, the combination therapy had no obvious effect on the platelet aggregation but could significantly extend the APTT, PT, and TT. Conclusion SDP has some inhibition on platelet aggregation with anticoagulant effect; Combined with Warfarin sodium, SDP has a synergistic interaction on anticoagulant effect with Warfarin sodium.

天津市科技创新专项资金项目:舒脑欣滴丸大品种系统开发(08FDZDSH01405);长江学者和创新团队发展计划资助(IRT 14R41)